Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback